Article Details
Retrieved on: 2024-01-25 22:02:47
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article summarizes the evolving market of relapsed/refractory multiple myeloma (RRMM), highlighting emerging biopharma therapies (including Elotuzumab and others) and their potential impact on market dynamics within the biopharma industry, as companies like Celgene, AbbVie, and Amgen develop new treatments.
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here